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Abstract
Marfan syndrome (MS) is a dominant autosomal disease caused by mutations in chromosome 15, the locus controlling fibrillin 
1 synthesis, and may exhibit skeletal, ocular, cardiovascular, and other manifestations. Pulse wave velocity (PWV) is used to 
measure arterial elasticity and stiffness and is related to the elastic properties of the vascular wall. Since the practice of exercise 
is limited in MS patients, it was of interest to analyze the acute effect of submaximal exercise on aortic distensibility using PWV 
and other hemodynamic variables in patients with MS with either mild or no aortic dilatation. PWV and physiological variables 
were evaluated before and after submaximal exercise in 33 patients with MS and 18 controls. PWV was 8.51 ± 0.58 at rest and 
9.10 ± 0.63 m/s at the end of exercise (P = 0.002) in the group with MS and 8.07 ± 0.35 and 8.98 ± 0.56 m/s in the control group, 
respectively (P = 0.004). Comparative group analysis regarding PWV at rest and at the end of exercise revealed no statistically 
significant differences. The same was true for the group that used β-blockers and the one that did not. The final heart rate was 
10% higher in the control group than in the MS group (P = 0.01). Final systolic arterial pressure was higher in the control group 
(P = 0.02). PWV in MS patients with mild or no aortic dilatation did not differ from the control group after submaximal effort.
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Marfan syndrome is a dominant autosomal disease 
caused by mutations in chromosome 15, the locus control-
ling fibrillin 1 synthesis, and may exhibit skeletal, ocular, 
cardiovascular, skin, neurological, and pulmonary manifes-
tations; patients often have a family history of the condition 
(1). Cardiovascular complications in Marfan syndrome may 
include mitral valve prolapse and regurgitation, dilatation 
of the pulmonary artery and mainly dilatation of the root of 
the aorta, which is the major cause of death in individuals 
affected by the syndrome (2). Pulse wave velocity (PWV) 
is used as a measure of arterial elasticity and stiffness and 
is related to the elastic properties of the vascular wall (3). A 
number of studies have demonstrated a variation in arterial 
elasticity in patients with isolated systolic hypertension and 
post-acute myocardial infarction (4,5). A reduction in aortic 
distensibility, as measured by PWV in patients with Marfan 
syndrome, has been reported (6,7).
The 2005 Guidelines of the 36th Bethesda Conference 
in the field of sports cardiology recommend that patients 
with Marfan syndrome and aortic dilatation greater than 40 
mm (in adults) only play sports such as golf, billiards and 
bowling, as these sports offer no potential risk of bodily 
collisions (8,9). As the practice of exercise is treated with 
caution in this population and there are practically no studies 
on this issue, it was of interest to analyze the acute effect 
of submaximal exercise on aortic distensibility using PWV 
and hemodynamic parameters in patients with Marfan 
syndrome with either mild or no aortic dilatation.
Patients and Methods
A controlled, cross-sectional study was carried out 
involving 39 patients with Marfan syndrome evaluated 
between August and September 2006. All patients were in 
treatment at the clinics of the Cardiology and Genetics sec-
tors of Universidade Federal de São Paulo (SP, Brazil). Six 
patients were under 12 years of age and were excluded from 
the study. Thirty-three patients (17 men) fulfilled the eligibility 
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criteria for participation in the study. The eligibility criteria 
required patients to have either a normal aorta or minimal 
dilatation (less than 37 mm, as determined by an echocar-
diogram), with no prior dissection, a recent echocardiogram 
(previous 6 months), the absence of signs and symptoms of 
cardiac ischemia, neurological or motor disorders, and not 
having undergone heart surgery. Echocardiogram measures 
were obtained on the root of the aorta (Valsalva sinus) and 
were carried out by a single examiner not involved in the 
study, using the methodology and reference values of the 
Echocardiography Sector, Cardiology Division, UNIFESP, 
and previous studies (10,11).
Among the 33 patients, 16 used β-blockers (propranolol 
or atenolol) and one used a β-blocker and angiotensin recep-
tor antagonist (losartan). A group of 18 healthy individuals 
(9 men) paired for gender, age, and weight was selected 
as the control group. The study was approved by the Eth-
ics Committee of the institution. All participants received 
information on the procedures to be carried out and signed 
a term of informed consent, which was also approved by 
the Ethics Committee for the present study.
Pulse wave velocity
PWV was determined by means of a noninvasive analy-
sis of the propagation time and distance of the pulse wave 
between two acquisition points [PWV = distance (m) / time 
(s)]. The transducers were positioned over the carotid and 
femoral arteries, always on the right side of the body and 
the signals were sent to the Complior system (France) 
(12). Signal acquisition was performed by a skilled observer 
who was unaware of the patient’s condition (5,13). The 
measurements were obtained with the patient in a lying 
position before and after exertion on a stationary bike, with 
15 sequential pulse waves preferentially recorded. The indi-
vidual returned to the evaluation bed for the acquisition of the 
data as soon as the predicted heart rate (HR) was reached 
or other exercise interruption criteria were fulfilled.
Exercise protocol
The individuals were submitted to an incremental test 
limited by HR, which was calculated by the equation: 
HRsubmax = 195 - age. If the patient was taking β-blockers, 
the calculated value was adjusted by the formula: %HR to 
correct = y + 95.58/9.74, in which y is the daily amount of 
medication (in milligrams) the patient takes (14). The ex-
ercise was performed on a stationary bike (Queens® - QH 
1000, Brazil), with progressive increments in intensity every 
2 min using the load control of the device. The participants 
were instructed to maintain a speed of 60 revolutions per 
minute. The exercise was interrupted when the participant 
reached the pre-calculated HR or manifested any signs 
or symptoms of exhaustion, dyspnea, fatigue, myocardial 
ischemia, blood pressure equal to or above 160 x 100 
mmHg (15), or reached 14 min of exercise.
Hemodynamic variables and blood lactate 
Physiological variables, HR and blood pressure were 
recorded after the patient remained at rest in a lying position 
for 5 min, when seated prior to beginning the exercise, at 
the time of interruption, and after 1 min of recovery. HR was 
obtained using a heart monitor (Polar® - S 810, Finland) 
and blood pressure was determined using the ausculta-
tion method with a sphygmomanometer and stethoscope 
(Tycos®, USA) (16). Blood lactate was determined from a 
blood sample obtained by puncture of the ring finger on the 
right hand while at rest, in the sitting position and at the time 
of interruption of exercise, using a lactometer (Accutrend® 
Lactate, Roche, USA).
Statistical analysis
The values of the variables considered for the analysis 
of HR, blood pressure and blood lactate were obtained with 
the individuals seated on the stationary bike at pre-test rest 
or at the time of interruption of exercise. Pulse wave time 
and velocity were obtained with the individuals lying down. 
Descriptive analysis is reported as the mean ± SD in absolute 
and percent values and presented in the tables.
The Kolmogorov-Smirnov test was employed in order 
to determine the normality of the data. Homogeneity of 
the sample was determined using the Levine test. For the 
analysis of the influence of systolic arterial pressure on 
the behavior of PWV, analysis of covariance (ANCOVA) 
was used, followed by the Bonferroni post hoc test when 
necessary. A paired Student t-test was used for intragroup 
inferential analysis and an independent Student t-test was 
used for intergroup analysis. A P value ≤0.05 was consid-
ered to be significant.
Results
Table 1 presents the anthropometric data and echocar-
diogram measurements at the root of the aorta. The anthro-
pometric analysis only revealed a significant difference in 
height between the two groups (P = 0.02; Table 1).
Seventeen (51%) patients in the group with Marfan 
Table 1. Anthropometric and echocardiographic data of patients 
with Marfan syndrome and controls.
Marfan (N = 33) Control (N = 18)
Age (years) 19 ± 8 20 ± 5
Weight (kg) 60.9 ± 12.6 62.4 ± 11.9
Height (m) 1.78 ± 0.10* 1.71 ± 0.10
BMI (kg/m2) 19.32 ± 3.93 21.28 ± 2.63
ECHO (mm) 33 ± 7* 28 ± 2
Data are reported as means ± SD. BMI = body mass index; 
ECHO = echocardiogram. *P ≤ 0.05 compared to control group 
(t-test). 
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syndrome were taking β-blockers and their predicted HR 
were corrected by the previously described formula. Of 
the 33 patients, 14 (42%) interrupted the exertion test by 
having reached the predicted HR, 8 due to peripheral limita-
tion (leg fatigue), 7 for having reached the predetermined 
blood pressure level and 4 due to respiratory exhaustion 
(dyspnea). In the control group, 11 participants (61%) in-
terrupted the test for having reached the predicted HR, 4 
for having reached the limit of 14 min of exercise, 1 due to 
peripheral limitation (leg fatigue), 1 due to dyspnea, and 1 
test was interrupted when the participant’s blood pressure 
reached 200 x 80 mmHg. 
Pulse wave propagation time and velocity
The analysis of the propagation time and velocity of the 
pulse wave revealed different values at rest and at the end 
of exercise in both the patients with Marfan syndrome and 
the control group. The patients with Marfan syndrome had 
a PWV of 8.51 ± 0.58 at rest and 9.10 ± 0.63 m/s at the end 
of exercise (P = 0.002), while the pulse wave propagation 
time in this group was 78.27 ± 4.98 at rest and 73.48 ± 5.57 
ms at the end of exercise (P = 0.015). In the control group, 
PWV was 8.07 ± 0.35 at rest and 8.98 ± 0.56 m/s at the 
end of the exercise (P = 0.004), while the propagation time 
was 79.22 ± 3.93 at rest and 71.50 ± 4.76 ms at the end 
of exercise (P = 0.012). Adjustment of PWV together with 
the final systolic arterial pressure revealed variation in this 
variable when the patients were at rest and at the end of 
exertion similar to the findings for PWV alone (ANCOVA; 
P = 0.0001; Figure 1).
Comparative analysis of PWV revealed no significant 
differences between groups while at rest or at the end of 
exercise (ANCOVA). Similarly, there were no significant 
differences in pulse wave propagation time between groups 
at rest and at the end of exercise.
Heart rate, blood lactate and exercise time
The predicted HR was calculated for all individuals. The 
mean value reached by the patients with Marfan syndrome 
and the control group was 90% of the predicted HR (P = 
0.44). There were no significant differences between groups 
regarding HR values while at rest. Final HR values were 
10% higher in the control group than in the individuals with 
Marfan syndrome (P = 0.01). There were no significant dif-
ferences between groups regarding HR values after 1 min 
of recovery (Table 2). There were significant differences 
between the control group and patients using β-blockers 
regarding HR values while at rest (P = 0.04), at the end of 
the exercise (P = 0.01) and during the recovery phase (P 
= 0.02). As expected, no significant differences in HR were 
found between the control group and patients who did not 
use β-blockers (Table 3). Exercise time was the sum of 
time spent in the test plus recovery time. Mean exercise 
time was 10.10 min for the control group compared to 8.44 
min for the group with Marfan syndrome (P = 0.01; Table 
Figure 1. Pulse wave velocity values at rest and at the end of 
exercise for the patients with Marfan syndrome (N = 33) and for 
the control group (N = 18). Data are reported as absolute values. 
*P < 0.05 compared to rest (t-test).
Table 2. Physiological variables at rest, at the end of exercise and during the first minute of recovery.
Marfan (N = 33) Control (N = 18) P pred P rest P final P rec 1 min
Pred/%at Rest Final Rec 1 min Pred/%at Rest Final Rec 1 min
HR (bpm) 176 ± 8/90 ± 11 72 ± 11 144 ± 21 121 ± 20a 175 ± 5/90 ± 13 78 ± 12 160 ± 24 132 ± 20 0.34/0.44 0.08 0.01* 0.10
SAP (mmHg) 105 ± 11 143 ± 19 125 ± 16c 110 ± 13 157 ± 21 136 ± 18 0.16 0.02*
DAP (mmHg) 72 ± 10 82 ± 13 74 ± 10c 69 ± 8 81 ± 6 71 ± 7 0.33 0.24
Lactate (mmol/L) 3.1 ± 0.9 6.4 ± 3.0b 3.3 ± 1.1 7.3 ± 2.7 0.45 0.67
Ex. time (min) 8.44 ± 2.24b 10.10 ± 2.26 0.01
Data are reported as means ± SD. HR = heart rate; SAP = systolic blood pressure; DAP = diastolic blood pressure; Ex. time = exercise 
time; Pred/%at = predicted heart rate/% of predicted heart rate attained; Rec 1 min = heart rate 1 min recovery. aN = 28; bN = 32; cN = 
29. *P ≤ 0.05 compared to control group (t-test).
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2). No significant difference was found between groups 
regarding blood lactate values while at rest or at the end 
of exercise (Table 2).
Systolic and diastolic arterial pressure
There were no significant differences between the group 
with Marfan syndrome and the control group regarding 
resting systolic and diastolic arterial pressure values (P = 
0.16 and P = 0.34). Systolic arterial pressure at the end 
of the exercise was 157 ± 21 mmHg in the control group 
and 143 ± 19 mmHg in the group with Marfan syndrome, 
demonstrating a statistically significant difference between 
groups (P = 0.02; Table 2). There was no statistically signifi-
cant difference between groups regarding diastolic arterial 
pressure at the end of the exercise.
Discussion
The present study demonstrated that individuals with 
Marfan syndrome who have either a normal aorta or mild 
aortic dilatation develop degrees of PWV similar to those of 
healthy individuals when performing acute exercise of mod-
erate intensity. The physiological response patterns during 
exercise were maintained in both groups, even when taking 
into consideration that approximately half of the individuals 
with Marfan syndrome used β-blockers. Marfan syndrome 
patients using β-blockers had significantly lower HR values 
at the end of exercise compared to the control group.
Aortic disease is one of the main complications and the 
major cause of death in patients with Marfan syndrome (17). 
The analysis of PWV has been proposed to be an adequate 
tool for assessing arterial distensibility in healthy individu-
als and those with diseases that affect the cardiovascular 
system (18,19). Using a transesophageal echocardiogram 
with patients at rest, Franke et al. (20) found lesser dis-
tensibility in asymptomatic patients with Marfan syndrome 
when compared to healthy individuals.
The analysis of resting PWV in the present study re-
vealed no statistically significant differences between the 
group of patients with Marfan syndrome and the control 
group. This suggests a similar distensibility pattern between 
the two populations when at rest, even in cases of patients 
with mild aortic dilatation. However, the numerical results 
of the present study cannot be compared directly to those 
reported by Franke et al. (20) since the methods for analysis 
were different. 
The PWV values obtained from measurements taken 
immediately after patients had lain down (in order to pro-
vide adequate quality for the measurements) at the end of 
exercise were elevated in both groups when compared to 
resting values. This suggests an acute increase in arterial 
stiffness with the exertion performed and demonstrates 
that the established exercise was sufficient to cause 
changes in arterial elasticity. Analyzing the acute effect 
of isometric grip strength exercises, Lydakis et al. (21) 
found a reduction in the transition time of the pulse wave, 
thereby suggesting an increase in the stiffness of central 
arteries. Other publications have also reported an increase 
in PWV and aortic stiffness in normal sedentary individu-
als and athletes performing exercises (22-24). However, 
the increase in blood pressure during exercise is a factor 
interfering with the variation of PWV and aortic distensibil-
ity, since the increase in pulse pressure leads to a greater 
demand on the elastin/collagen structure of the central 
arteries (25). Furthermore, the increase in wave velocity 
found in the presence of an increase in arterial stiffness 
results in a premature return of the reflection wave while 
still in the systolic phase, thereby producing an increase in 
systolic arterial pressure (26). In the present study, there 
was an increase in systolic arterial pressure at the end of 
exercise and the maintenance of diastolic arterial pressure, 
with a consequent variation in pulse pressure, which is in 
agreement with the aforementioned findings. Analysis of 
covariance of the adjustment in PWV together with the final 
systolic arterial pressure revealed changes in this variable 
when the patients of both groups were at rest and at the 
end of exertion similar to that for PWV alone.
The comparison of resting and final PWV values of 
patients with Marfan syndrome who used β-blockers and 
patients with Marfan syndrome who did not use this medica-
tion revealed no statistically significant differences between 
the two subgroups.
We believe that the PWV values were not different from 
the control group, not even when at rest, because the aortic 
alterations in this population were either not yet sufficient 
to affect the distensibility or stiffness of the aorta or were 
suppressed by the use of β-blockers.
The chronotropic response and systolic arterial pres-
sure of the patients with Marfan syndrome in relation to 
the submaximal effort employed proved to be slightly 
reduced when compared to that of the control group. This 
finding may have occurred because of a poorer degree of 
cardiovascular conditioning, which is corroborated by the 
shorter total exercise time achieved by the group with Marfan 
Table 3. Heart rate values for the control group and for patients 
with Marfan syndrome taking or not β-blockers.
Heart rate (bpm)
Control 
(N = 18)
No β-blockers 
(N = 16)
With β-blockers 
(N = 17)
Rest 78 ± 12 75 ± 10 69 ± 11*
End of exercise 160 ± 24 150 ± 20 139 ± 21*
Recovery 132 ± 20 127 ± 20b 114 ± 17a*
Data are reported as means ± SD. aN = 13; bN = 15. *P ≤ 0.05 
compared to control group (t-test).
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syndrome. Furthermore, these patients are instructed by 
their cardiologists not to perform any type of moderate or 
intense physical activity, which may also have influenced 
this finding due to the fact that they have a more sedentary 
lifestyle (27). We should also consider that 17 patients used 
β-blockers and had their predicted HR adjusted. However, 
no statistical differences were found in resting or final HR 
between patients with Marfan syndrome who used this 
medication and those who did not. Phelps et al. (28) found 
considerable variability in the pharmacokinetics of atenolol 
in patients with and without Marfan syndrome, which may 
have influenced the results of the present study.
Analysis of the increase in blood lactate revealed no 
statistically significant differences between the Marfan 
syndrome and control groups. However, the levels found 
may suggest that the participants had reached higher than 
expected degrees of exertion, inferring a greater cardiovas-
cular load (15). This increase in lactate also corroborates 
the fact that the effort made was effective and caused 
metabolic alterations.
A limitation of the present study may have been the 
time for determining the curves as soon as the patient had 
returned to bed. Due to the increased HR, the machine often 
selected two curves at the same time, which prevented im-
mediate acceptance by the system and resulted in a new 
acquisition command. Moreover, the instrument used for 
the evaluation of PWV may not have had sufficient sensitiv-
ity to identify alterations in the distensibility and stiffness 
of the aorta expected in this population. This point may 
suggest that PWV is not a good method for the analysis of 
acute aortic distensibility even with the partial correction 
by ANCOVA. Furthermore, even these corrections of PWV 
may still not be considered by some as a good measure 
to assess acute changes in vascular compliance. The 
number of patients with Marfan syndrome able to perform 
the exercise, together with the exclusion criteria, limited 
the number of participants. Likewise, it is currently difficult 
to encounter patients with Marfan syndrome who do not 
use β-blockers, which is why we chose to include patients 
who took this medication. This decision also provided the 
opportunity to compare findings between patients with 
Marfan syndrome with and without the use of β-blockers 
as an initial hypothesis of the study. Another limitation was 
that the load control on the stationary bike did not allow 
direct adjustments, which, in turn, did allow an analysis of 
HR levels and loads.
The present study demonstrates that patients with 
Marfan syndrome and either a normal aorta or mild aortic 
dilatation (as assessed by an echocardiogram) exhibit aortic 
distensibility similar to that of sedentary control individuals 
when performing submaximal exercise. However, these 
patients exhibited lower chronotropic and blood pressure 
responses than controls, possibly due to a lesser degree 
of physical effort in daily activities (with a consequent lack 
of physical conditioning), along with the use of β-blockers. 
Analysis of the results demonstrates that the immediate 
effects of moderate-intensity exercise on individuals with 
Marfan syndrome did not lead to different results from 
those achieved by the control population, especially among 
patients who did not use β-blockers. The beneficial effects 
of a regular physical exercise program without pronounced 
loads or risk of bodily collision may produce cardiovascular 
adaptations that favor the quality of life of these individuals. 
An analysis of the results obtained here and those encoun-
tered in the literature leads us to believe in the protective 
role therapeutic exercise may provide to these individuals. 
However, further studies should utilize more sophisticated 
methods and equipment to be adequately validated and 
should be carried out employing adequate exercise as a 
complementary therapy in the treatment of Marfan syn-
drome. No complications were found during this protocol 
in Marfan patients.
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